Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

20260 citationsJournal Article

Authors

Thomas Walter · Centre National de la Recherche Scientifique

Julien Mazieres · Université Toulouse III - Paul Sabatier

Josiane Otto · Centre Antoine Lacassagne

H. Léna · Inserm

Côme Lepage · Maison des Sciences sociales et des Humanités de Dijon

D. Smith · Centre Hospitalier Universitaire de Bordeaux

J. Madelaine

Abstract

Nivolumab-ipilimumab could be a second-/third-line treatment option for patients with NECs. However, given the limited magnitude of benefit, studies are warranted to evaluate its use earlier and/or associated with chemotherapy.

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Esophageal Cancer Research and Treatment

Publication Details

Published in: Journal of Clinical Oncology

DOI: 10.1200/jco-25-01657

Field-Weighted Citation Impact: 0.00

Command Palette

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Authors

Abstract

Topics & Keywords

Publication Details